
Layla Soroush
Examiner (ID: 2180, Phone: (571)272-5008 , Office: P/1627 )
| Most Active Art Unit | 1627 |
| Art Unit(s) | 1627, 1622, 1617 |
| Total Applications | 1220 |
| Issued Applications | 393 |
| Pending Applications | 177 |
| Abandoned Applications | 690 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 20163826
[patent_doc_number] => 20250255872
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-08-14
[patent_title] => TOPICAL FORMULATION FOR JAK INHIBITOR
[patent_app_type] => utility
[patent_app_number] => 19/171214
[patent_app_country] => US
[patent_app_date] => 2025-04-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9893
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19171214
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/171214 | TOPICAL FORMULATION FOR JAK INHIBITOR | Apr 4, 2025 | Pending |
Array
(
[id] => 20092044
[patent_doc_number] => 20250221980
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-07-10
[patent_title] => METHODS FOR ENHANCING THE BIOAVAILABILITY AND EXPOSURE OF A VOLTAGE-GATED POTASSIUM CHANNEL OPENER
[patent_app_type] => utility
[patent_app_number] => 19/094303
[patent_app_country] => US
[patent_app_date] => 2025-03-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23818
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19094303
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/094303 | METHODS FOR ENHANCING THE BIOAVAILABILITY AND EXPOSURE OF A VOLTAGE-GATED POTASSIUM CHANNEL OPENER | Mar 27, 2025 | Pending |
Array
(
[id] => 20231280
[patent_doc_number] => 20250288599
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-09-18
[patent_title] => PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING OSTEOARTHRITIS
[patent_app_type] => utility
[patent_app_number] => 19/079370
[patent_app_country] => US
[patent_app_date] => 2025-03-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19065
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -32
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19079370
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/079370 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING OSTEOARTHRITIS | Mar 12, 2025 | Pending |
Array
(
[id] => 20039147
[patent_doc_number] => 20250177369
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-06-05
[patent_title] => ORAL LIQUID FORMULATION OF APIXABAN
[patent_app_type] => utility
[patent_app_number] => 19/044129
[patent_app_country] => US
[patent_app_date] => 2025-02-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2517
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 41
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19044129
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/044129 | ORAL LIQUID FORMULATION OF APIXABAN | Feb 2, 2025 | Pending |
Array
(
[id] => 19954394
[patent_doc_number] => 12324790
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2025-06-10
[patent_title] => Preparation method and application of micelle preparation containing thymol and derivative thereof
[patent_app_type] => utility
[patent_app_number] => 18/974530
[patent_app_country] => US
[patent_app_date] => 2024-12-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 1802
[patent_no_of_claims] => 3
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 115
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18974530
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/974530 | Preparation method and application of micelle preparation containing thymol and derivative thereof | Dec 8, 2024 | Issued |
Array
(
[id] => 19954394
[patent_doc_number] => 12324790
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2025-06-10
[patent_title] => Preparation method and application of micelle preparation containing thymol and derivative thereof
[patent_app_type] => utility
[patent_app_number] => 18/974530
[patent_app_country] => US
[patent_app_date] => 2024-12-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 1802
[patent_no_of_claims] => 3
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 115
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18974530
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/974530 | Preparation method and application of micelle preparation containing thymol and derivative thereof | Dec 8, 2024 | Issued |
Array
(
[id] => 20048197
[patent_doc_number] => 20250186419
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-06-12
[patent_title] => DOSING REGIMENS FOR TREATING PAIN
[patent_app_type] => utility
[patent_app_number] => 18/972540
[patent_app_country] => US
[patent_app_date] => 2024-12-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 73596
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 31
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18972540
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/972540 | DOSING REGIMENS FOR TREATING PAIN | Dec 5, 2024 | Pending |
Array
(
[id] => 20048197
[patent_doc_number] => 20250186419
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-06-12
[patent_title] => DOSING REGIMENS FOR TREATING PAIN
[patent_app_type] => utility
[patent_app_number] => 18/972540
[patent_app_country] => US
[patent_app_date] => 2024-12-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 73596
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 31
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18972540
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/972540 | DOSING REGIMENS FOR TREATING PAIN | Dec 5, 2024 | Pending |
Array
(
[id] => 20023106
[patent_doc_number] => 20250161328
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-05-22
[patent_title] => NASAL SPRAY COMPOSITION
[patent_app_type] => utility
[patent_app_number] => 18/955763
[patent_app_country] => US
[patent_app_date] => 2024-11-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9892
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 74
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18955763
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/955763 | NASAL SPRAY COMPOSITION | Nov 20, 2024 | Pending |
Array
(
[id] => 20023106
[patent_doc_number] => 20250161328
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-05-22
[patent_title] => NASAL SPRAY COMPOSITION
[patent_app_type] => utility
[patent_app_number] => 18/955763
[patent_app_country] => US
[patent_app_date] => 2024-11-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9892
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 74
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18955763
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/955763 | NASAL SPRAY COMPOSITION | Nov 20, 2024 | Pending |
Array
(
[id] => 20432523
[patent_doc_number] => 12502395
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-12-23
[patent_title] => Progestin/testosterone transdermal gel
[patent_app_type] => utility
[patent_app_number] => 18/941896
[patent_app_country] => US
[patent_app_date] => 2024-11-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 4056
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 34
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18941896
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/941896 | Progestin/testosterone transdermal gel | Nov 7, 2024 | Issued |
Array
(
[id] => 20432523
[patent_doc_number] => 12502395
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-12-23
[patent_title] => Progestin/testosterone transdermal gel
[patent_app_type] => utility
[patent_app_number] => 18/941896
[patent_app_country] => US
[patent_app_date] => 2024-11-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 4056
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 34
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18941896
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/941896 | Progestin/testosterone transdermal gel | Nov 7, 2024 | Issued |
Array
(
[id] => 19784118
[patent_doc_number] => 20250057797
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-02-20
[patent_title] => STABLE LEVOTHYROXINE COMPOSITIONS IN APROTIC POLAR SOLVENTS
[patent_app_type] => utility
[patent_app_number] => 18/934749
[patent_app_country] => US
[patent_app_date] => 2024-11-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20828
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18934749
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/934749 | Stable levothyroxine compositions in aprotic polar solvents | Oct 31, 2024 | Issued |
Array
(
[id] => 19845157
[patent_doc_number] => 20250090508
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-03-20
[patent_title] => METHODS OF REDUCING ITCH USING TOPICAL ROFLUMILAST COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 18/884931
[patent_app_country] => US
[patent_app_date] => 2024-09-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12585
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 50
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18884931
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/884931 | METHODS OF REDUCING ITCH USING TOPICAL ROFLUMILAST COMPOSITIONS | Sep 12, 2024 | Abandoned |
Array
(
[id] => 19830832
[patent_doc_number] => 20250082618
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-03-13
[patent_title] => DOSING REGIMENS USING TOPICAL ROFLUMILAST COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 18/827222
[patent_app_country] => US
[patent_app_date] => 2024-09-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9814
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 57
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18827222
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/827222 | DOSING REGIMENS USING TOPICAL ROFLUMILAST COMPOSITIONS | Sep 5, 2024 | Pending |
Array
(
[id] => 19798891
[patent_doc_number] => 20250064816
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-02-27
[patent_title] => PHARMACEUTICAL RECTAL SUPPOSITORY COMPOSITIONS OF 6-THIOGUANINE, METHODS OF TREATMENT AND/OR METHODS OF MANUFACTURING
[patent_app_type] => utility
[patent_app_number] => 18/814130
[patent_app_country] => US
[patent_app_date] => 2024-08-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25890
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18814130
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/814130 | PHARMACEUTICAL RECTAL SUPPOSITORY COMPOSITIONS OF 6-THIOGUANINE, METHODS OF TREATMENT AND/OR METHODS OF MANUFACTURING | Aug 22, 2024 | Pending |
Array
(
[id] => 19599467
[patent_doc_number] => 20240390347
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-28
[patent_title] => AMLODIPINE FORMULATIONS
[patent_app_type] => utility
[patent_app_number] => 18/794128
[patent_app_country] => US
[patent_app_date] => 2024-08-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32488
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 171
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18794128
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/794128 | Amlodipine formulations | Aug 4, 2024 | Issued |
Array
(
[id] => 19599467
[patent_doc_number] => 20240390347
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-28
[patent_title] => AMLODIPINE FORMULATIONS
[patent_app_type] => utility
[patent_app_number] => 18/794128
[patent_app_country] => US
[patent_app_date] => 2024-08-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32488
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 171
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18794128
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/794128 | Amlodipine formulations | Aug 4, 2024 | Issued |
Array
(
[id] => 19682435
[patent_doc_number] => 20250000980
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-01-02
[patent_title] => TOPICAL OPHTHALMOLOGICAL COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 18/768656
[patent_app_country] => US
[patent_app_date] => 2024-07-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4943
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18768656
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/768656 | Topical ophthalmological compositions | Jul 9, 2024 | Issued |
Array
(
[id] => 19462364
[patent_doc_number] => 20240316033
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-26
[patent_title] => METHODS FOR ENHANCING THE BIOAVAILABILITY AND EXPOSURE OF A VOLTAGE-GATED POTASSIUM CHANNEL OPENER
[patent_app_type] => utility
[patent_app_number] => 18/679045
[patent_app_country] => US
[patent_app_date] => 2024-05-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28026
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18679045
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/679045 | METHODS FOR ENHANCING THE BIOAVAILABILITY AND EXPOSURE OF A VOLTAGE-GATED POTASSIUM CHANNEL OPENER | May 29, 2024 | Pending |